Search
Selected Filter
Displaying 51–60 of 285 research results
-
Foundation Awarded 21 New Grants in FY2021 Totaling More than $14.2 Million
Eye On the Cure Research NewsCurrent research portfolio is comprised of nearly 100 projects at prominent institutions around the world
-
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Eye On the Cure Research NewsVisit www.LUMEOSstudy.com for more information about trial
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Eye On the Cure Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Eye On the Cure Research NewsEarly, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Eye On the Cure Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Eye On the Cure Research News
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Eye On the Cure Research NewsAdditional results from the trial will be reported at a future scientific meeting
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Eye On the Cure Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Eye On the Cure Research NewsMore details from the clinical trial will be reported at a later date
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Eye On the Cure Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
.png)
